This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (49)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology, Other  • Alert me on articles by topic

Recent Advances

Andrew G. Engel, MD; Kinji Ohno, MD, PhD; Steven M. Sine, PhD

Arch Neurol. 1999;56:163-167.

Congenital myasthenic syndromes (CMS) can arise from presynaptic, synaptic, or postsynaptic defects. Mutations of the acetylcholine receptor (AChR) that increase or decrease the synaptic response to acetylcholine (ACh) are a common cause of the postsynaptic CMS. An increased response occurs in the slow-channel syndromes. Here, dominant mutations in different AChR subunits and in different domains of the subunits prolong the activation episodes of AChR by either delaying channel closure or increasing the affinity of AChR for ACh. A decreased synaptic response to ACh occurs with recessive, loss-of-function mutations. Missense mutations in the low-affinity, fast-channel syndrome and in a disorder associated with mode-switching kinetics of AChR result in brief activation episodes and reduce the probability of channel opening. Mutations causing premature termination of the translational chain or missense mutations preventing the assembly or glycosylation of AChR curtail the expression of AChR. These mutations are concentrated in the subunit, probably because substitution of the fetal for the adult subunit can rescue humans from fatal null mutations in . Recent molecular genetic studies have also elucidated the pathogenesis of the CMS caused by absence of the asymmetric form of acetylcholinesterase from the synaptic basal lamina. Endplate acetylcholinesterase deficiency is now known to be caused by mutations in the collagenic tail subunit of the asymmetric enzyme that prevents the association of the collagenic tail subunit with the catalytic subunit or its insertion into the basal lamina.

From the Department of Neurology and Neuromuscular Disease Laboratory (Drs Engel and Ohno) and the Receptor Biology Laboratory, Department of Physiology and Biophysics (Dr Sine), Mayo Clinic and Mayo Foundation, Rochester, Minn.

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(2):254-255.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The RNA-binding Protein HuR Binds to Acetylcholinesterase Transcripts and Regulates Their Expression in Differentiating Skeletal Muscle Cells
Deschenes-Furry et al.
J. Biol. Chem. 2005;280:25361-25368.
ABSTRACT | FULL TEXT  

Diagnosis of Congenital Myasthenic Syndrome
Millichap
AAP Grand Rounds 2004;11:54-54.
FULL TEXT  

Expression of foetal type acetylcholine receptor is restricted to type 1 muscle fibres in human neuromuscular disorders
Gattenlohner et al.
Brain 2002;125:1309-1319.
ABSTRACT | FULL TEXT  

A newly identified chromosomal microdeletion and an N-box mutation of the AChR{epsilon} gene cause a congenital myasthenic syndrome
Abicht et al.
Brain 2002;125:1005-1013.
ABSTRACT | FULL TEXT  

A common mutation ({epsilon}1267delG) in congenital myasthenic patients of Gypsy ethnic origin
Abicht et al.
Neurology 1999;53:1564-1564.
ABSTRACT | FULL TEXT  

Chromosome 17p-linked myasthenias stem from defects in the acetylcholine receptor {epsilon}-subunit gene
Middleton et al.
Neurology 1999;53:1076-1076.
ABSTRACT | FULL TEXT  

Recent Advances in Understanding Congenital Myasthenic Syndromes
JWatch Neurology 1999;1999:7-7.
FULL TEXT